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Objective: A higher BMI has become acknowledged as one of the impor-
tant risk factors for developing critical condition in coronavirus disease 
2019 (COVID-19). In addition to BMI, body composition, and particularly 
visceral adiposity, might be an even more accurate measure to stratify 
patients. Therefore, the aim of this study was to evaluate the association 
between the distributions of computed-tomography-quantified fat mass 
and critical condition of patients with COVID-19.
Methods: A systematic search was conducted in five databases for 
studies published until November 17, 2020. In the meta-analysis, pooled 
mean difference (standardized mean difference [SMD]) of visceral fat area 
(VFA; in square centimeters) was calculated between patients in the in-
tensive care unit and those in general ward and between patients with the 
requirement for invasive mechanical ventilation (IMV) and those without 
the IMV requirement.
Results: The quantitative synthesis revealed that patients requiring in-
tensive care had higher VFA values (SMD = 0.46, 95% CI: 0.20-0.71, 
P < 0.001) compared with patients on the general ward. Similarly, patients 
requiring IMV had higher VFA values (SMD = 0.38, 95% CI: 0.05-0.71, 
P = 0.026) compared with patients without the IMV requirement.
Conclusions: VFA values were found to be significantly higher in patients 
with critical condition. Therefore, abdominal adiposity seems to be a risk 
factor in COVID-19, and patients with central obesity might need special 
attention.
Obesity (2021) 29, 521-528. 
Introduction
With the escalation of the pandemic caused by severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2), recognizing risk factors is of utmost importance. Among other 
risk factors such as age and comorbidities (1,2), a higher BMI has been acknowledged as 
a risk factor for developing critical condition in coronavirus disease 2019 (COVID-19) in 
our former analysis and in other articles since then (3-6). Because the obesity epidemic is 
rapidly spreading worldwide, it is vital to accurately identify patients with a higher risk for 
developing critical condition in COVID-19.
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Study Importance
What is already known?
►	A higher BMI was found to be a risk fac-
tor for developing critical condition in 
COVID-19.
►	Because the prevalence of obesity is in-
creasing worldwide, it is vital to identify 
patients at a higher risk.
►	Several studies have proposed that vis-
ceral adiposity might be a risk factor.
What does this study add?
►	We performed a comprehensive search, 
selection, and quantitative and qualita-
tive analysis concerning the association 
between computed-tomography-quan-
tified fat mass distribution and critical 
condition among COVID-19 patients.
►	Pooled analysis of three studies revealed 
that patients requiring intensive care or 
invasive mechanical ventilation had 
higher visceral fat area values compared 
with patients without the need for them.
How might these results change the 
direction of research or the focus of 
clinical practice?
►	Although BMI is widely used to define 
obesity, further phenotyping of patients, 
for example by assessing body com-
position and central obesity, might be 
recommended.
►	Considering the potential role of visceral 
adipose tissue, it might also be worth 
studying adipose-tissue-related sub-
stances as potential pharmacological 
targets.
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Although BMI is widely used to diagnose obesity (7), body com-
position, and especially visceral adiposity, might be an even more 
accurate measure to stratify patients (8-12). Therefore, we aimed 
to evaluate the association between the distributions of computed 
tomography (CT)-quantified fat mass and critical condition of 
patients with COVID-19.
Methods
We report this meta-analysis and systematic review according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
Statement (13).
Search strategy
A systematic search was conducted in MEDLINE (via PubMed), 
Embase, Cochrane Library (CENTRAL), Scopus, and Web of Science 
for studies published until November 17, 2020. The following search 
terms were used in all databases: ((“covid 19”) OR (“Wuhan virus”) 
OR (“coronavirus”) OR (“2019 nCoV”) OR (“SARS-cov-2”)) AND 
((fat OR obes* OR adipos*) AND (visceral OR intraabdominal OR 
abdominal OR central)). There was no restriction applied to the 
search.
Selection and eligibility criteria
We selected clinical studies reporting on patients hospitalized with 
confirmed SARS-CoV-2 infection (based on the World Health 
Organization case definition) and on the distribution of body fat mass 
assessed by CT. Studies were included in the meta-analysis if data on 
the following variables were reported: the number of patients with 
and without critical condition (defined as the need for invasive me-
chanical ventilation [IMV] or admission to intensive care unit [ICU]) 
and distribution of body fat mass (total adipose tissue [TAT], vis-
ceral adipose tissue [VAT], subcutaneous adipose tissue [SAT]). The 
latter parameters could be reported as thickness (millimeters), area 
(square centimeters), or volume (cubic centimeters). Abstracts and 
grey literature (preprints and other non-peer-reviewed material) were 
excluded from the analysis.
The yield of the search was combined in a reference manager software 
(EndNote X9; Clarivate Analytics, Philadelphia, Pennsylvania). After 
automatic and manual removal of duplicate records, full texts of all 
studies were evaluated by two independent review authors. Two review 
authors decided to include a study in the meta-analysis if they agreed. A 
third author resolved the disagreements. Reference lists of the included 
studies were screened for additional eligible articles.
Data extraction
Two independent review authors extracted data into a standardized 
data collection form (Microsoft Excel 365, Microsoft Corporation, 
Redmond, Washington). The following data were extracted from each 
eligible article: first and second authors; publication year; study site; 
sex; age; the number of patients with and without critical condition; 
and the means, standard deviations, medians, ranges, and interquartile 
ranges related to body fat mass (the article provided thickness in mil-
limeters, area in square centimeters, and volume in cubic centimeters 
of TAT, VAT, and SAT). Odds ratios (ORs) and risk ratios (with the 
corresponding confidence intervals) relating to the association between 
body fat mass and critical condition were also extracted. A third party 
resolved discrepancies. The authors of the eligible articles were not 
contacted for further information.
Quality assessment
Quality of the eligible studies was evaluated by using the Quality in 
Prognosis Studies (QUIPS) tool by two independent review authors 
(14). Any disagreement was resolved by third-party arbitration.
Statistical analysis
Cohen’s kappa coefficient (κ) was calculated to measure interrater reli-
ability during the selection process. κ ≤ 0 is interpreted as no agreement, 
0.01-0.20 as none to slight agreement, 0.21-0.40 as fair agreement, 0.41-
0.60 as moderate agreement, 0.61-0.80 as substantial agreement, 0.81-
1.00 as almost perfect agreement, and 1.00 as perfect agreement (15).
We calculated pooled mean difference (standardized mean difference 
[SMD]) for continuous variables because the CT examinations were 
performed at different vertebral levels among studies. We used random 
effect model with the DerSimonian-Laird estimation (16). Statistical 
heterogeneity was calculated performing the I2 test, and we also carried 
out χ2 tests to acquire probability values: P < 0.1 indicated significant 
heterogeneity. The interpretation of I2 was as follows: 0% to 40%: not 
important; 30% to 60%: moderate heterogeneity; 50% to 90%: substan-
tial heterogeneity; and 75% to 100%: considerable heterogeneity (17). 
If the mean with standard deviation could not be extracted, we esti-
mated them from median, interquartiles, and range using the method 
by Wan et al. (18).
Results
Systematic search and selection
The results of the systematic search and selection are shown in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
Flowchart (Figure 1). The calculated κ value based on the full-text se-
lection was 1.00, which was interpreted as perfect agreement. On com-
pletion of the selection, six studies, including data from 560 patients, 
were eligible. The characteristics of the studies included are summa-
rized in Table 1. Five out of six studies, including 509 patients, reported 
on ICU admission rate, which ranged between 18.5% and 43.3%. Three 
studies with 208 patients reported on IMV requirement in the associ-
ation with body composition metrics. The visceral fat area (VFA; in 
cubic centimeres) values ranged between 70.9 cm2 and 240 cm2. The 
results of the quantitative and qualitative synthesis are shown in Table 1, 
Table 2, and Figure 2.
VAT mass and COVID-19
Our quantitative synthesis revealed that patients requiring inten-
sive care had higher VFA values (SMD = 0.46, 95% CI: 0.20-0.71, 
P < 0.001) compared with patients on the general ward. Similarly, pa-
tients requiring IMV had higher VFA values (SMD = 0.38, 95% CI: 
0.05-0.71, P = 0.022) compared with patients without IMV require-
ment. Statistical heterogeneity might not be important in any analysis 
(I2 = 0.0%, P = 0.637 and  I2 = 0.0%, P = 0.747 for ICU admission and 
IMV, respectively). These results are depicted in Figure 2. Two stud-
ies found, in age- and gender-adjusted analyses, that an increased 
VFA carries a higher risk for ICU admission (11,19). Yang et al. did 
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not identify VFA > 100 mm2 as a significant risk factor for ICU admis-
sion (OR = 1.94, 95% CI: 0.95-4.05). (32). Battisti et al. also found a 
higher visceral fat thickness (in millimeters) among patients admitted 
to the ICU compared with patients on the general ward (13.1 ± 6 mm vs. 
17.9 ± 6.5 mm, P < 0.001) (8).
SAT mass and COVID-19
Watanabe et al. found that an increased subcutaneous fat area (SFA) 
is not associated with a higher risk for ICU admission (19). Yang 
et al. did not identify SFA > 100 mm2 as a risk factor for ICU admission 
(OR = 1.06, 95% CI: 0.52-2.17) (32). However, a high VFA/SFA ratio 
was found to be associated with an increased risk for ICU admission 
(OR = 2.47, 95% CI = 1.05-5.98) (9).
TAT mass and COVID-19
Two studies evaluated total fat area (TFA) in COVID-19 patients. 
Petersen et al. revealed that every additional 10 cm2 of TFA carries 
1.13 times (95% CI: 1.03-1.29) and 1.28 times (95% CI: 1.06-1.80) 
additional risk for ICU admission and IMV requirement, respectively 
(11). Another study identified an increased TFA as a risk factor for ICU 
Figure 1 PRISMA flowchart for the study selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-
Analyses. [Color figure can be viewed at wileyonlinelibrary.com]
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admission in univariate and age- and sex-adjusted multivariate logistic 
regression analysis (19).
Risk of bias assessment
The overall risk of bias was low to moderate in the studies included. 
Detailed results of the quality assessment are found in Supporting 
Information.
Discussion
Our most important finding is that VFA was higher in patients admitted 
to the ICU and requiring IMV, which draws attention to the importance 
of abdominal adiposity in COVID-19.
A recent meta-analysis by Huang et al. has come to the same conclu-
sion (20); they have found higher VAT values in patients with critical 
condition, as well. However, their search interval was shorter, and we 
included two additional studies in the meta-analyses (9,11). They did 
not change the direction of the results but rather confirmed the previ-
ous findings. A further strength of our study is that, unlike Huang et 
al., we pooled only those studies that reported on VFA (in square cen-
timeters), whereas we excluded from the meta-analysis those stud-
ies that reported visceral fat thickness (in millimeters), preventing 
biases resulting from combining values reported in different units of 
measures. Thereby, the possible distortion owing to indirectness was 
minimized. In addition, we performed a qualitative synthesis con-
cerning the effects of fat distribution (VAT, SAT, and TAT values) on 
the outcomes.
There are several theories proposed to explain how abdominal obesity 
leads to adverse outcomes in COVID-19.
The malfunction of VAT can impair the immune system by producing 
different inflammatory substances and adipokines (21). The unhealthy 
expansion of adipose tissue is associated with endoplasmic reticulum 
stress, adipose tissue fibrosis, and localized hypoxia (22). In turn, it is 
associated with adipocyte cell death and inflammatory response initi-
ation (23). An increase in monocyte chemoattractant protein-1 in VAT 
contributes to macrophages’ infiltration, predominantly M1 macro-
phages, which promote inflammation, generate reactive oxygen spe-
cies, and release pro-inflammatory cytokines, such as tumor necrosis 
factor-α and interleukin-6. In contrast, lean adipose tissue contains 
M2 macrophages predominantly, showing anti-inflammatory activity. 
Besides, in obesity, inflammation-inducing leptin release increases, 
whereas protective adiponectin production declines.
The emerging low-grade chronic inflammation may contribute to the 
“cytokine storm” in severe COVID-19 cases (24) and increases the 
vulnerability to infections as well as to metabolic and cardiovascular 
complications, such as insulin resistance, type 2 diabetes mellitus, 
microvascular disorders, or progressive atherosclerosis (25). These dis-
eases are also recognized as risk factors in COVID-19 (1). Angiotensin-
converting enzyme 2 receptors are also abundant in adipose tissue, 
contributing to more severe infection and disease course (26).
Moreover, visceral obesity is associated with a complex pro-coagulant 
and a suppressed fibrinolytic profile (because of, among other reason, 
extensive endothelial damage, enhanced estrogen, and plasmin activa-
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Severe abdominal obesity also leads to restrictive ventilator disorders 
with decreased chest compliance and low respiratory reserve (reduced 
vital capacity and forced expiratory volume in 1 second), which may 
aggravate lung complications in COVID-19 (28).
In addition to CT-quantified VAT, other indicators of abdominal obesity, 
such as waist circumference and waist-hip ratio, would be worth further 
investigation since they are easily applicable in routine clinical practice 
(10,11,29-31).
Our study has some limitations. First, this difference mentioned ear-
lier is difficult to interpret without adjusting for BMI and other risk 
factors such as age, gender, or comorbidities. Nonetheless, most of 
the included studies performed multivariate analysis, and they mostly 
agreed on that visceral adiposity might be an independent risk factor 
for adverse outcomes. Second, we could not perform meta-analyses 
related to TAT, SAT, VAT/TAT ratio, or VAT/SAT ratio in the absence 
of a sufficient number of studies. However, our qualitative synthesis 
suggested that SAT does not carry a risk of critical condition. Third, 
we could only combine those studies in the meta-analysis that evalu-
ated VAT by area, which resulted in the exclusion of a study reporting 
on VAT thickness (8). Finally, the small number of included studies 
remained a limitation.
In summary, we found that VFA values were significantly higher 
in patients with critical condition. In light of the high prevalence of 
TABLE 2 Summary of the qualitative synthesis and results of the individual studies
Study first author and 
year Risk factor Outcome
Sample 
size Results of the study
Battisti et al. (2020) (8) VAT thickness (per mm increase) ICU 144 OR = 1.16 (95% CI: 1.07-1.26)*
*Multivariate analysis: adjusted for gender, age,  
and BMI
20% VAT/SAT increase ICU 144 OR = 1.25 (95% CI: 1.1-1.42)*
*Multivariate analysis: adjusted for gender, age, and 
BMI
Deng et al. (2020) (12) SAT higher than 10 mm ICU 65 P = 1.0
VAT CT density higher than 107 HU ICU 65 P = 0.706
Petersen et al. (2020) (11) VAT (per 10 cm2) ICU 30 OR = 1.36 (95% CI: 1.08-1.86)
OR = 1.37 (95% CI: 1.07-1.89)*
*Multivariate analysis: adjusted for gender and age
TAT (per 10 cm2) ICU 30 OR = 1.11 (95% CI: 1.02-1.28)
OR = 1.13 (95% CI: 1.03-1.29)*
*Multivariate analysis: adjusted for gender and age
VAT (per 10 cm2) IMV 30 OR = 1.30 (95% CI: 1.05-1.81)
OR = 1.32 (95% CI: 1.04-1.91)*
*Multivariate analysis: adjusted for gender and age
TAT (per 10 cm2) IMV 30 OR = 1.08 (95% CI: 0.99-1.19)
OR = 1.28 (95% CI: 1.06-1.80)*
*Multivariate analysis: adjusted for gender and age
Watanabe et al. (2020) 
(19)
VAT (mm2) ICU/IMV 127 OR = 3.13 (95% CI: 1.36-7.19)
OR = 1.57 (95% CI: 1.0.5-2.37)*
OR = 2.47 (95% CI: 1.02-6.02)**
*Multivariate analysis: adjusted for gender and age
**Multivariate analysis: adjusted for age, gender, 
diabetes, hypertension, ACEi/ARB use
SAT (mm2) ICU/IMV 127 OR = 1.6 (95% CI: 0.73-3.5)
TAT (mm2) ICU/IMV 127 OR = 2.22 (95% CI: 0.99-4.93)
OR = 1.59 (95% CI: 1.06-2.39)*
*Multivariate analysis: adjusted for gender and age
Yang Y et al. (2020) (32) >100 cm2 VAT ICU 143 OR = 1.94 (95% CI: 0.95-4.05)
>100 cm2 SAT ICU 143 OR = 1.06 (95% CI: 0.52-2.17)
High VAT/SAT ratio ICU 143 OR = 2.32 (95% CI: 1.13-4.89)
OR = 2.47 (95% CI: 1.05-5.98)*
*Multivariate analysis: adjusted for age and gender
ACEi/ARB, angiotensin- converting enzyme inhibitors/angiotensin II receptor blockers; CI, confidence interval; CT, computed tomography; HU, Hounsfield unit; ICU, intensive 
care unit admission; IMV, invasive mechanical ventilation; OR, odds ratio; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; VAT, visceral adipose tissue.
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obesity, this area of research should be further investigated. Besides the 
distribution of body fat, adipose-tissue-related substances as potential 
pharmacological targets might be worth studying as well.O
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